News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon Beta-1b (NU100) in Relapsing Remitting Multiple Sclerosis


11/1/2011 7:28:58 AM

EXTON, Pa.--(BUSINESS WIRE)--Nuron Biotech Inc., a specialty biologics and vaccines company, today announced the initiation of a randomized, double-blind, placebo-controlled, pivotal Phase 3 study to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis (RRMS). NU100 is a proprietary recombinant human interferon beta-1b (IFN beta-1b) being developed as a new molecular entity. The product is an essentially aggregate-free liquid formulation produced utilizing an advanced processing technology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES